GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by Mengis Capital Management Inc.

Mengis Capital Management Inc. lifted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 31.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,362 shares of the company’s stock after buying an additional 10,685 shares during the period. Mengis Capital Management Inc.’s holdings in GE HealthCare Technologies were worth $3,468,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in GEHC. LGT Financial Advisors LLC increased its stake in GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in GE HealthCare Technologies during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies in the third quarter valued at approximately $26,000. Darwin Wealth Management LLC acquired a new position in GE HealthCare Technologies during the third quarter valued at approximately $31,000. Finally, Continuum Advisory LLC grew its stake in GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GEHC shares. Citigroup raised their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company upped their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $90.57 on Tuesday. The firm has a market cap of $41.42 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 3.19 and a beta of 1.15. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The business’s 50 day moving average is $85.26 and its two-hundred day moving average is $85.96. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.